GeneMedicine and Vanderbilt University Medical Center Collaborate on Pulmonary Gene Therapy

Strategic Insights -

GeneMedicine Inc., a pharmaceutical company specializing in gene therapy, has announced a collaborative agreement with Vanderbilt University Medical Center to develop pulmonary gene therapy methods. The partnership aims to explore the use of non-viral gene medicines to express the alpha-1 antitrypsin gene, which inhibits inflammatory damage to the lungs and could potentially prevent emphysema. GeneMedicine will supply plasmid DNA and gene delivery systems, including its proprietary cationic lipid, DOTMA, for Vanderbilt's clinical trial.

Key Takeaways:

  • GeneMedicine and Vanderbilt University Medical Center have signed a cooperative research agreement to develop pulmonary gene therapy methods.
  • The partnership aims to explore the use of non-viral gene medicines to express the alpha-1 antitrypsin gene, which inhibits inflammatory damage to the lungs.
  • GeneMedicine will supply plasmid DNA and gene delivery systems, including its proprietary cationic lipid, DOTMA, for Vanderbilt's clinical trial.
  • The study will be conducted at the Vanderbilt Center for Lung Research, directed by Professor Kenneth L. Brigham, M.D.
  • The partnership marks a significant milestone in GeneMedicine's pulmonary gene therapy initiative.
  • Professor Kenneth L. Brigham, M.D., will be the principal investigator of the clinical trial.
  • GeneMedicine's proprietary cationic lipid, DOTMA, will be used in the gene delivery technologies for the clinical trial.
  • The gene delivery technologies used in the study can be applied to many different therapeutic gene products expressed within the lung.

Statistics:

  • The Vanderbilt Center for Lung Research was established in April 1985.
  • GeneMedicine is developing a new class of pharmaceutical products that incorporate genes, called "gene medicines".
  • GeneMedicine's technologies have potential application in the development of gene therapy methods for a wide range of diseases and disorders.

Sources:

  • Business Wire, November 16, 1994
  • GeneMedicine Inc.
  • Vanderbilt University Medical Center